Abstract
Regulatory T- (T(REG)) cells are considered to inhibit the development of both type 1 and type 2 helper T (T(H1) and (TH2)) cells. However, the number of T(REG) cells in patients with allergic diseases who have high levels of serum IgE and blood eosinophils is reduced as compared to individuals who have similarly high levels of IgE and eosinophils but are asymptomatic. Therefore, T(REG) cells may suppress the onset of allergic disease by downregulating other types of immune cells besides T(H1) and T(H2) cells. The newly discovered interleukin (IL-)17-producing helper T- (T(H17)) cells responsible for autoimmune inflammatory diseases may counteract with T(REG) cells even in allergic diseases. T(H2) cells capable of producing of high levels of tumor necrosis factor (TNF)-alpha may also be involved in the inflammation in allergic diseases. In this review, the role of T(H1), T(H2), T(H17) and T(REG) cells in allergic diseases is further discussed by using the balancing square model and the factors differentiating between patients with clinical manifestations of allergic symptomatic versus atopic individuals who are sensitized but asymptomatic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
